CompletedNCT00036101
Aripiprazole for acute mood symptoms in bipolarity
About this title
Read the official source — NCT00036101Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Tuscaloosa and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00036101
- Official title
Show the full official title
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscaloosa · Little Rock · Beachwood
24 more locations
- Chula Vista
- Riverside
- San Clemente
- San Diego
- Stanford
- Washington D.C.
- North Miami
- Winter Park
- Honolulu
- Chicago
- Indianapolis
- Louisville
- Belmont
- Newton Center
- New Baltimore
- Lawrence
- Butner
- Cincinnati
- Medina
- Philadelphia
- Austin
- Houston
- Falls Church
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
